

May 10, 2023
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Onconova Therapeutics announces presentation of an overview of its investigator-sponsored clinical program evaluating rigosertib monotherapy in RDEB-associated SCC at the ISID International Epidermolysis Bullosa Symposium in Osaka

TOKYO, Japan, May 10, 2023 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, "Symbio") today announced that its U.S. licensor for rigosertib, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, "Onconova"), announced a presentation of an overview of its investigator-sponsored clinical trial evaluating rigosertib monotherapy in squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa (RDEB-associated SCC) at the International Symposium on Epidermolysis Bullosa of the International Society of Investigative Dermatology (ISID), held in Osaka, Japan on May 9, 2023 (Japan Standard Time).

Onconova plans to review these findings with regulators to determine the most expeditious path toward approval for rigosertib in RDEB-associated SCC.

For Onconova's full press release, please visit Onconova's website: <https://investor.onconova.com/press-releases>

About rigosertib

Rigosertib is a small molecule inhibitor that has a new mechanism of action: it inhibits the activation of RAS as an oncogene-related product, thereby blocking the action of multikinases, including PI3K, and inhibits cellular signaling in cancer cells necessary for their survival and proliferation, thus killing cancer cells. SymBio obtained the development and commercialization licensing rights for rigosertib from Onconova in July 2011 for Japan and Korea.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. For more information, please visit <https://www.onconova.com>

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, the Company incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Durham, North Carolina, President: Carolyn Yanavich).

The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.